172 related articles for article (PubMed ID: 27068870)
21. Depigmented and polymerised house dust mite allergoid: allergen content, induction of IgG4 and clinical response.
Gallego MT; Iraola V; Himly M; Robinson DS; Badiola C; García-Robaina JC; Briza P; Carnés J
Int Arch Allergy Immunol; 2010; 153(1):61-9. PubMed ID: 20357486
[TBL] [Abstract][Full Text] [Related]
22. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma.
Wang L; Yin J; Fadel R; Montagut A; de Beaumont O; Devillier P
Allergy; 2014 Sep; 69(9):1181-8. PubMed ID: 25056584
[TBL] [Abstract][Full Text] [Related]
23. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy.
Nieto A; Mazón Á; Nieto M; Ibáñez E; Jang DT; Calaforra S; Alba P; Pérez-Francés C; Llusar R; Montoro J; de Mateo A; Alamar R; El-Qutob D; Fernández J; Moral L; Toral T; Antón M; Andreu C; Ferrer Á; Flores IM; Cerdá N; Del Pozo S; Caballero R; Subiza JL; Casanovas M
Allergy; 2022 Oct; 77(10):3096-3107. PubMed ID: 35570712
[TBL] [Abstract][Full Text] [Related]
24. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients.
Pfaar O; Nell MJ; Boot JD; Versteeg SA; van Ree R; Roger A; Riechelmann H; Sperl A; Oude Elberink JN; Diamant Z; Bachert C
Allergy; 2016 Jul; 71(7):967-76. PubMed ID: 26864207
[TBL] [Abstract][Full Text] [Related]
25. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children.
Corzo JL; Carrillo T; Pedemonte C; Plaza Martin AM; Martín Hurtado S; Dige E; Calderon MA
J Investig Allergol Clin Immunol; 2014; 24(3):154-61. PubMed ID: 25011352
[TBL] [Abstract][Full Text] [Related]
26. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.
Matsuoka T; Bernstein DI; Masuyama K; Nolte H; Okamiya K; Seitzberg D; Nelson HS
Pediatr Allergy Immunol; 2017 Nov; 28(7):661-667. PubMed ID: 28660739
[TBL] [Abstract][Full Text] [Related]
27. Recent development on the use of sublingual immunotherapy tablets for allergic rhinitis.
Waserman S; Shah A; Avilla E
Ann Allergy Asthma Immunol; 2021 Aug; 127(2):165-175.e1. PubMed ID: 34029713
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial.
La Grutta S; Arena A; D'Anneo WR; Gammeri E; Leonardi S; Trimarchi A; Platania D; La Rosa M
Eur Ann Allergy Clin Immunol; 2007 Feb; 39(2):40-4. PubMed ID: 17441414
[TBL] [Abstract][Full Text] [Related]
29. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
30. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial.
Demoly P; Corren J; Creticos P; De Blay F; Gevaert P; Hellings P; Kowal K; Le Gall M; Nenasheva N; Passalacqua G; Pfaar O; Tortajada-Girbés M; Vidal C; Worm M; Casale TB
J Allergy Clin Immunol; 2021 Mar; 147(3):1020-1030.e10. PubMed ID: 32890575
[TBL] [Abstract][Full Text] [Related]
31. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
32. Immunological effects of adjuvanted low-dose allergoid allergen-specific immunotherapy in experimental murine house dust mite allergy.
Heldner A; Alessandrini F; Russkamp D; Heine S; Schnautz B; Chaker A; Mwange J; Carreno Velazquez TL; Heath MD; Skinner MA; Kramer MF; Zissler UM; Schmidt-Weber CB; Blank S
Allergy; 2022 Mar; 77(3):907-919. PubMed ID: 34287971
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, placebo controlled trial of sublingual immunotherapy with house-dust mite extract for allergic rhinitis.
Guo Y; Li Y; Wang D; Liu Q; Liu Z; Hu L
Am J Rhinol Allergy; 2017 Jul; 31(4):42-47. PubMed ID: 28716168
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy for house-dust mite allergy.
Nelson HS
Allergy Asthma Proc; 2018 Jul; 39(4):264-272. PubMed ID: 30095391
[TBL] [Abstract][Full Text] [Related]
35. A Three-Year Course of House Dust Mite Sublingual Immunotherapy Appears Effective in Controlling the Symptoms of Allergic Rhinitis.
Novakova SM; Novakova PI; Yakovliev PH; Staevska MT; Mateva NG; Dimcheva TD; Peichev JL
Am J Rhinol Allergy; 2018 May; 32(3):147-152. PubMed ID: 29649893
[TBL] [Abstract][Full Text] [Related]
36. SQ house dust mite sublingual immunotherapy for the treatment of adults with house dust mite-induced allergic rhinitis.
Meteran H; Backer V
Expert Rev Clin Immunol; 2019 Nov; 15(11):1127-1133. PubMed ID: 31584839
[No Abstract] [Full Text] [Related]
37. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Sublingual Immunotherapy in the Treatment of HDM-Induced Nasobronchial Allergies: A 3-Year Randomized Case-Control Study From Kashmir.
Baba SM; Rasool R; Gull A; Qureshi TA; Beigh AH; Qadri Q; Shah ZA
Front Immunol; 2021; 12():723814. PubMed ID: 34721385
[TBL] [Abstract][Full Text] [Related]
39. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis.
Riechelmann H; Schmutzhard J; van der Werf JF; Distler A; Kleinjans HA
Am J Rhinol Allergy; 2010; 24(5):e104-9. PubMed ID: 21244725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]